Longeveron Inc. (LGVN)
- Previous Close
1.5600 - Open
1.6000 - Bid 1.1400 x 200
- Ask 2.0300 x 200
- Day's Range
1.5850 - 1.6000 - 52 Week Range
0.7710 - 6.4000 - Volume
19,295 - Avg. Volume
251,832 - Market Cap (intraday)
23.708M - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.88
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
longeveron.comRecent News: LGVN
View More
Performance Overview: LGVN
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LGVN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LGVN
View MoreValuation Measures
Market Cap
23.33M
Enterprise Value
5.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.14
Price/Book (mrq)
1.07
Enterprise Value/Revenue
2.32
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-54.87%
Return on Equity (ttm)
-111.59%
Revenue (ttm)
2.39M
Net Income Avi to Common (ttm)
-24.62M
Diluted EPS (ttm)
-2.6200
Balance Sheet and Cash Flow
Total Cash (mrq)
19.23M
Total Debt/Equity (mrq)
6.61%
Levered Free Cash Flow (ttm)
-9.27M